Lexeo Therapeutics (LXEO) CMO Narinder Pal Bhalla files Form 3 showing no holdings

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. filed an initial insider ownership report for its Chief Medical Officer, Narinder Pal Bhalla. The filing states that, as of the event date of 01/20/2026, no securities of Lexeo Therapeutics are beneficially owned by this reporting person.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bhalla Narinder Pal

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 6TH FLOOR

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/20/2026

3. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Youjin Choi, Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Lexeo Therapeutics (LXEO) Form 3 filed for Narinder Pal Bhalla show?

The Form 3 shows that Chief Medical Officer Narinder Pal Bhalla reports no beneficial ownership of Lexeo Therapeutics securities as of January 20, 2026. This establishes his initial insider ownership status under Section 16 reporting rules.

Who is the insider named in the Lexeo Therapeutics (LXEO) Form 3?

The insider is Narinder Pal Bhalla, who is identified as an officer of Lexeo Therapeutics with the title Chief Medical Officer. The filing is made as a Form 3, which is an initial statement of beneficial ownership for insiders.

Does the Lexeo Therapeutics (LXEO) Form 3 report any shares owned by Narinder Pal Bhalla?

No, the Form 3 explicitly states in the explanation of responses that no securities are beneficially owned. This means Bhalla reports zero direct or indirect ownership of Lexeo Therapeutics securities as of the relevant event date.

What is the event date for the Narinder Pal Bhalla Form 3 at Lexeo Therapeutics (LXEO)?

The event date requiring the Form 3 statement is January 20, 2026. This date is used as the reference point for determining and disclosing Narinder Pal Bhalla’s beneficial ownership status in Lexeo Therapeutics securities.

What is the relationship of Narinder Pal Bhalla to Lexeo Therapeutics (LXEO) in the Form 3?

The filing identifies Narinder Pal Bhalla as an officer of Lexeo Therapeutics, with the specific title Chief Medical Officer. He is not marked as a director or 10% owner, and the form is filed by one reporting person.